To develop a blood-based measure of phosphorylated tau217 for predicting the onset of symptomatic Alzheimer's disease.
Key Findings:
P-tau217 levels rise progressively during the preclinical phase of Alzheimer's and accelerate as symptom onset approaches.
The predictive performance of p-tau217 clocks was consistent across diverse study populations.
P-tau217 levels were associated with established imaging and cerebrospinal fluid markers of Alzheimer's pathology.
Interpretation:
The study indicates that blood tests for p-tau217 can serve as a feasible and accessible method for predicting Alzheimer's onset, potentially aiding in early intervention strategies.
Limitations:
The study may require further validation in larger, more diverse populations.
Long-term clinical outcomes based on p-tau217 predictions need to be established.
Conclusion:
The use of blood tests for p-tau217 could revolutionize the early detection of Alzheimer's, allowing for timely intervention and personalized care plans.
